Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1954 1
1955 1
1956 1
1961 1
1963 2
1964 6
1965 2
1966 1
1967 1
1968 1
1969 4
1971 5
1975 3
1978 1
1981 2
1982 1
1983 3
1984 1
1985 1
1993 2
1994 1
1995 1
1996 1
1997 4
1998 8
1999 16
2000 7
2001 10
2002 4
2003 6
2004 12
2005 15
2006 9
2007 16
2008 16
2009 33
2010 41
2011 48
2012 46
2013 52
2014 50
2015 48
2016 75
2017 83
2018 95
2019 89
2020 100
2021 153
2022 126
2023 81
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

1,162 results

Results by year

Filters applied: . Clear all
Page 1
S1 Guideline: Diagnosis and therapy of vitiligo.
Böhm M, Schunter JA, Fritz K, Salavastru C, Dargatz S, Augustin M, Tanew A. Böhm M, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2022 Mar;20(3):365-378. doi: 10.1111/ddg.14713. Epub 2022 Mar 4. J Dtsch Dermatol Ges. 2022. PMID: 35246935
S2k guideline: Diagnosis and treatment of chronic pruritus.
Ständer S, Zeidler C, Augustin M, Darsow U, Kremer AE, Legat FJ, Koschmieder S, Kupfer J, Mettang T, Metz M, Nast A, Raap U, Schneider G, Ständer H, Streit M, Schut C, Weisshaar E. Ständer S, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2022 Oct;20(10):1387-1402. doi: 10.1111/ddg.14830. J Dtsch Dermatol Ges. 2022. PMID: 36252071 Free article.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Duell J, et al. Among authors: augustin m. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958. Haematologica. 2021. PMID: 34196165 Free PMC article. Clinical Trial.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: augustin m. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H, Fröhling S. Horak P, et al. Among authors: augustin m. Cancer Discov. 2021 Nov;11(11):2780-2795. doi: 10.1158/2159-8290.CD-21-0126. Epub 2021 Jun 10. Cancer Discov. 2021. PMID: 34112699
Dokumentation der Psoriasis in der Routineversorgung - Expertenkonsens zu einem deutschen Datensatz.
Otten M, Mrowietz U, von Kiedrowski RM, Otto R, Altenburg A, Aschoff R, Beissert S, Beiteke U, Bonnekoh B, Hoffmann M, Körber A, Maaßen D, Mössner R, Navarini A, Petering H, Ramaker-Brunke J, Rosenbach T, Schwichtenberg U, Sticherling M, Sondermann W, Thaci D, Timmel A, Tsianakas A, Werfel T, Wilsmann-Theis D, Augustin M. Otten M, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2021 Oct;19(10):1463-1477. doi: 10.1111/ddg.14547_g. J Dtsch Dermatol Ges. 2021. PMID: 34661349 German.
Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 1: Therapieziele und Therapieempfehlungen.
Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. Nast A, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2021 Jun;19(6):934-951. doi: 10.1111/ddg.14508_g. J Dtsch Dermatol Ges. 2021. PMID: 34139080 German. No abstract available.
Aktualisierung„ Systemtherapie bei Neurodermitis“ zur S2k-Leitlinie Neurodermitis.
Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H. Werfel T, et al. Among authors: augustin m. J Dtsch Dermatol Ges. 2021 Jan;19(1):151-169. doi: 10.1111/ddg.14371_g. J Dtsch Dermatol Ges. 2021. PMID: 33491881 Free article. German.
1,162 results